Boston Scientific Shares Surge After $540M Acquisition of SoniVie to Boost Hypertension Innovations
1min read Boston Scientific recently announced its acquisition of the Israeli medical device company SoniVie Ltd., marking a significant move in the hypertension treatment landscape. The acquisition helps solidify Boston Scientific’s commitment to innovative therapeutic solutions, particularly in the field of renal denervation (RDN) for the treatment of hypertension through minimally invasive procedures.
This strategic acquisition involves boston scientific purchasing the remaining 90% of SoniVie’s shares for $540 million, having previously held a 10% stake. SoniVie specializes in TIVUS™ intravascular ultrasound technology, a promising approach currently under trial that seeks to address various hypertension-related conditions by targeting nerves around the blood vessels. The technology positions itself as an alternative or complementary treatment to traditional hypertension medication.
The TIVUS system is designed to emit focused ultrasonic energy through circulating blood, safely denervating the nerves surrounding the renal artery, which potentially lowers cardiovascular risks associated with hyperactive sympathetic nervous systems. Importantly, this method differentiates itself from conventional radiofrequency systems by offering deeper tissue penetration, which could enhance the efficacy and safety of nerve ablation procedures.
Despite the potential advantages of this technology, the journey to commercial success is still in its early days. The RDN sector itself is on the brink of significant growth, with expectations for a steep compound annual growth rate by the end of the decade. Boston Scientific’s entry into this promising yet competitive market highlights a pivotal moment as it competes against other market leaders with differing technological approaches.
As healthcare continues to evolve towards more personalized and precision-oriented solutions, Boston Scientific's move may catalyze further innovation and investment within the RDN market. This acquisition also reiterates the company's pursuit of expanding its cardiology and peripheral interventions portfolio, aiming to offer broader and more effective treatment options to patients worldwide suffering from hypertension.
